Not included in the above types listed are metastatic cancers; this is because metastatic cancer cells usually arise from a cell type listed above and the major difference from the above types is that these cells are now present in a tissue from which the cancer cells did not originally develop. Consequently, if the terms "metastatic cancer" is used, for accuracy, the tissue from which the cancer cells arose should be included. For example, a patient may say they have or are diagnosed with "metastatic cancer" but the more accurate statement is "metastatic (breast, lung, colon, or other type) cancer with spread to the organ in which it has been found." Another example is the following: A doctor describing a man whose prostate cancer has spread to his bones should say the man has metastatic prostate cancer to bone. This is not "bone cancer," which would be cancer that started in the bone cells. Metastatic prostate cancer to bone is treated differently than lung cancer to bone.
Success stories like Oliver’s are everywhere, but there’s not a lot of data to back up those results. That’s because CBD comes from cannabis and, like nearly all other parts of the plant, is categorized by the Drug Enforcement Agency (DEA) as a Schedule 1 drug—the most restrictive classification. (Others on that list: heroin, Ecstasy, and peyote.) This classification, which cannabis advocates have tried for years to change, keeps cannabis-derived products, including CBD, from being properly studied in the U.S.
If you haven’t been bombarded with CBD marketing or raves about it from friends, get ready. This extract—which comes from either marijuana or its industrial cousin, hemp—is popping up everywhere. There are CBD capsules, tinctures, and liquids for vaping plus CBD-infused lotions, beauty products, snacks, coffee, and even vaginal suppositories. Already some 1,000 brands of CBD products are available in stores—and online in states that don’t have lenient cannabis laws. This is a tiny fraction of what’s to come: The CBD market is poised to exceed $1 billion by 2020, per the Chicago-based research firm Brightfield Group.
One study of over 100 patients with osteoarthritis in the hip compared a five-week manual therapy program, including manipulations and joint mobilization, to an exercise program. Eighty-one percent of individuals had general perceived improvement after manual therapies, while only 50% experienced that in the exercise group. Patients in the manual therapy group had significantly better outcomes on pain, stiffness, hip function, and range of motion. These improvements lasted through at least 29 weeks.
Cannabidiol (CBD) is one of dozens of non-psychoactive cannabinoids found in the hemp plant. Cannabidiol, and all the other cannabinoids, were patented by the United States Government in 2003 as neuroprotectants and antioxidants (Patent No. 6,630,507). Cannabinoids are characterized by their ability to act on the cannabinoid receptors that are found throughout the body. CBD and other cannabinoids are naturally occurring compounds that display potent anti-inflammatory and pain-relieving properties. They can promote the body’s healthy regulation of the central nervous, immune, and endocannabinoid systems.